Bryan Kobel Net Worth 2026: Salary, Stock Ownership & Controversy

Who Is Bryan Kobel?

Bryan Kobel is the Chief Executive Officer of TC Biopharm (Holdings) Plc, a biopharmaceutical company specializing in treatments for neurological and inflammatory diseases. Appointed in June 2021, Kobel has led the company through a Nasdaq IPO in February 2022 and continues to steer its growth in a competitive industry. His career includes a stint as Managing Director at EF Hutton, where he oversaw healthcare investment banking from October 2020 to June 2021.

Kobel’s educational background includes a BA in Economics from Emory University and an MBA from the Wharton School of the University of Pennsylvania. His leadership has positioned TC Biopharm as a player in the biotech sector, though his financial profile remains closely tied to the company’s stock performance and market fluctuations.

Bryan Kobel’s 2026 Net Worth Estimate

As of 2026, Bryan Kobel’s net worth is estimated at £1.2 million, derived from his salary, stock ownership, and the financial outcomes of his professional ventures. His annual compensation of £427.17K (as reported in August 2025) includes £355.975K in fixed salary and £71.195K in bonuses. Additionally, his direct ownership of 0.44% of TC Biopharm shares, valued at €3.54K, contributes to his net worth. However, the 2025 Uber lawsuit, in which he sued the company over an alleged assault by an undocumented driver, may introduce financial uncertainties.

The IPO he led in 2022 also plays a role in his wealth. While the exact financial gains from the IPO are not publicly disclosed, his role as CEO likely granted him stock options and equity stakes that fluctuate with the company’s market value. The biotech sector’s volatility further complicates net worth projections, as TC Biopharm’s stock price directly affects Kobel’s holdings.

Compensation Breakdown: Salary vs. Bonuses

Bryan Kobel’s compensation structure, as reported in August 2025, includes a total annual pay of £427.17K. This is split into 83.3% salary (£355.975K) and 16.7% bonuses (£71.195K). The salary is fixed, while the bonuses are tied to performance metrics and company milestones. This breakdown aligns with typical executive compensation models in the biotech industry, where bonuses often incentivize leadership to meet strategic goals.

The salary and bonuses are supplemented by stock options and equity, though specific figures for these components are not disclosed. For context, Kobel’s compensation compares to industry peers in biotech, where CEOs typically earn between £300K and £600K annually, depending on company size and market performance. His 2022 IPO leadership likely added significant long-term value through equity grants.

Stock Ownership and IPO Impact

Bryan Kobel’s direct ownership of 0.44% in TC Biopharm (Holdings) Plc, valued at €3.54K as of August 2025, is a minor but tangible component of his net worth. This stake is subject to market fluctuations, meaning his actual wealth tied to the company could rise or fall with stock price movements. As of 2026, the company’s stock price has not been disclosed, but historical data from 2025 indicates moderate volatility typical of the biotech sector.

The 2022 Nasdaq IPO was a pivotal event for Kobel. While IPOs often generate substantial wealth for executives through stock sales and liquidity events, Kobel’s specific gains remain undisclosed. However, his role as CEO likely granted him additional shares or options post-IPO, which could amplify his net worth if the stock appreciates. Conversely, regulatory restrictions and lock-up periods may limit immediate financial gains.

The Uber Lawsuit: Financial Risks

In 2025, Bryan Kobel sued Uber after alleging an assault by an undocumented driver during a ride. The lawsuit, detailed in media outlets, highlights potential financial risks beyond his corporate role. While the legal costs and settlement details are not public, such incidents could affect investor confidence in TC Biopharm or Kobel’s personal reputation. The biotech industry, which relies heavily on public trust and investor backing, may perceive such controversies as a risk to leadership stability.

Though the lawsuit’s direct financial impact on Kobel is unclear, legal battles can drain resources through court fees, settlements, or reputational damage. For a CEO, this could indirectly affect stock value if stakeholders perceive leadership as prone to high-risk behaviors. However, Kobel’s continued tenure at TC Biopharm suggests the incident has not yet disrupted his professional trajectory.

10 Key Facts About Bryan Kobel’s Net Worth

1. Role at TC Biopharm

Bryan Kobel has served as CEO of TC Biopharm (Holdings) Plc since June 2021. His tenure spans 3.33 years as of 2026.

2. Annual Compensation

His total compensation in 2026 is £427.17K, comprising £355.975K in salary and £71.195K in bonuses. This equates to £35.597K monthly.

3. Stock Ownership

Kobel owns 0.44% of TC Biopharm shares, valued at €3.54K as of August 2025. This stake is subject to market fluctuations.

4. IPO Leadership

He led TC Biopharm’s Nasdaq IPO in February 2022, a critical event that likely enhanced his net worth through stock options and equity stakes.

5. Previous Role at EF Hutton

Before joining TC Biopharm, Kobel was Managing Director at EF Hutton from October 2020 to June 2021, overseeing healthcare investment banking.

6. Education Background

He holds a BA in Economics from Emory University and an MBA from the Wharton School of the University of Pennsylvania.

7. Company Focus

TC Biopharm specializes in biopharmaceutical treatments for neurological and inflammatory diseases, aligning with Kobel’s strategic focus areas.

8. Professional Network

MarketScreener lists three professional relationships for Kobel, though specific names and roles are not disclosed.

9. Industry Recognition

Kobel was quoted in *PharmExec* in July 2022 on challenges facing biotech fundraising, highlighting his public profile in the sector.

10. Controversy

The 2025 Uber lawsuit, though unrelated to his corporate role, could indirectly impact TC Biopharm’s investor sentiment. Legal controversies involving CEOs often raise questions about leadership stability and corporate governance, even if the issues are personal in nature.

FAQ: Common Questions About Bryan Kobel’s Net Worth

How much does Bryan Kobel earn as TC Biopharm’s CEO?

Bryan Kobel’s annual compensation in 2026 is £427.17K, split into £355.975K salary and £71.195K bonuses. This includes 83.3% fixed pay and 16.7% variable incentives.

What is Bryan Kobel’s stock ownership in TC Biopharm?

He owns 0.44% of TC Biopharm shares, valued at €3.54K as of August 2025. This stake is subject to market volatility.

How did Bryan Kobel’s IPO leadership impact his net worth?

Leading the 2022 Nasdaq IPO likely boosted Kobel’s net worth through stock options and equity stakes, though exact figures are not disclosed. IPOs often provide long-term financial gains for executives.

What controversies involve Bryan Kobel’s personal life?

Kobel sued Uber in 2025 after an alleged assault by an undocumented driver. The lawsuit highlights potential financial and reputational risks beyond his corporate role.

How does Bryan Kobel’s compensation compare to other biotech CEOs?

Kobel’s £427K annual pay aligns with industry averages for mid-sized biotech companies. Executives at larger firms often earn significantly more, while smaller companies may offer lower compensation.

What companies has Bryan Kobel worked for besides TC Biopharm?

Before joining TC Biopharm, Kobel served as Managing Director at EF Hutton from October 2020 to June 2021, focusing on healthcare investment banking.

How did Bryan Kobel’s education influence his career trajectory?

Kobel’s BA in Economics from Emory and MBA from Wharton provided a strong foundation in finance and leadership, positioning him for executive roles in the biotech sector.

What is TC Biopharm’s role in Bryan Kobel’s financial portfolio?

As CEO, Kobel’s financial profile is heavily tied to TC Biopharm’s stock performance. His 0.44% ownership and potential IPO gains make the company a central component of his net worth.

Conclusion: Final Verdict on Bryan Kobel’s Net Worth

Bryan Kobel’s 2026 net worth is estimated at £1.2 million, derived from his £427K annual salary, 0.44% stock ownership in TC Biopharm (€3.54K), and the financial outcomes of the 2022 IPO. While his compensation is in line with industry standards for mid-sized biotech companies, his net worth remains closely tied to the volatility of TC Biopharm’s stock price and market conditions.

The 2025 Uber lawsuit introduces potential financial uncertainties, though its direct impact on his net worth remains unclear. As a CEO in a high-risk industry, Kobel’s financial profile reflects the interplay of leadership, market dynamics, and personal controversies. For readers seeking to understand his net worth, the key takeaway is that it is a blend of steady income, stock value, and the unpredictable nature of biotech sector investments.